Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

Ozdede A., Yazici H.

NEW ENGLAND JOURNAL OF MEDICINE, vol.386, no.18, pp.1766, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Letter
  • Volume: 386 Issue: 18
  • Publication Date: 2022
  • Doi Number: 10.1056/nejmc2202778
  • Journal Name: NEW ENGLAND JOURNAL OF MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
  • Page Numbers: pp.1766
  • Istanbul University Affiliated: No

Abstract

To the Editor: An "organized skepticism" is a fundamental norm of scientific ethos(1) and an essential element of the open-science movement.(2) Inaccessibility of the informed consent form to the readers of an interventional controlled trial obstructs organized skepticism. This situation becomes more worrisome when the study in question is a safety outcome trial. There is good evidence that what informed consent entails is poorly understood by patients.(3) We believe that this understanding is further diminished when the trial that the patients are asked to participate in is a safety outcome trial, because in this setting, the patients are offered treatment . . .